Yes, you can use both Anoro and Symbicort together
Using Anoro (umeclidinium/vilanterol) and Symbicort (budesonide/formoterol) concurrently is appropriate and supported by COPD guidelines, as this constitutes triple therapy—a recommended treatment approach for patients with moderate to severe COPD who have frequent exacerbations or inadequate symptom control on dual therapy.
Understanding the Medication Classes
This combination provides three distinct bronchodilator and anti-inflammatory mechanisms:
Anoro contains:
- Umeclidinium (long-acting muscarinic antagonist/LAMA)
- Vilanterol (long-acting β-agonist/LABA)
Symbicort contains:
- Budesonide (inhaled corticosteroid/ICS)
- Formoterol (long-acting β-agonist/LABA)
The Critical Caveat: LABA Duplication
The major concern with this combination is that you would be receiving TWO long-acting β-agonists (vilanterol from Anoro AND formoterol from Symbicort), which creates unnecessary duplication and increases the risk of β-agonist side effects (tremor, tachycardia, hypokalemia, arrhythmias) 1.
The Preferred Approach
Instead of using both medications, you should use a single-inhaler triple therapy that contains LAMA + LABA + ICS without duplication. The 2023 Canadian Thoracic Society guidelines specifically recommend triple therapy (LAMA/LABA/ICS) for patients with stable COPD at high risk of exacerbations with moderate to high symptom burden 2.
Recommended Triple Therapy Options:
- Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) - once daily
- Budesonide/glycopyrrolate/formoterol (BUD/GLY/FORM) - twice daily
Recent real-world evidence shows FF/UMEC/VI was associated with 12% lower rate of moderate-severe COPD exacerbations compared to BUD/GLY/FORM 3, and 11% lower risk of all-cause mortality 3.
When Triple Therapy is Indicated
The American College of Chest Physicians and Canadian Thoracic Society guidelines support triple therapy for 4:
- Patients with moderate to very severe COPD (GOLD categories C and D)
- Those with ≥2 exacerbations per year or inadequate control on dual therapy
- Patients requiring step-up from ICS/LABA or LAMA/LABA combinations
Triple therapy has been shown to:
- Reduce exacerbation rates
- Improve lung function (reaching minimally important clinical thresholds)
- Enhance health-related quality of life
- Provide marginal mortality benefit 4
Safety Considerations
If you must use both medications temporarily (e.g., during a transition period), be aware of:
- Increased cardiovascular effects from dual LABA exposure (palpitations, tremor, QT prolongation)
- Hypokalemia risk, especially if also taking diuretics 1
- Pneumonia risk from ICS component (4% increased risk) 4
- Anticholinergic effects from umeclidinium (dry mouth, urinary retention, narrow-angle glaucoma) 1
Clinical Bottom Line
Contact your prescriber to consolidate your therapy into a single-inhaler triple therapy product rather than using both Anoro and Symbicort together. This eliminates LABA duplication, reduces pill burden, improves adherence, and maintains the therapeutic benefits of triple therapy with a better safety profile. The transition should be straightforward since you're already on the component medications.